ADAR1 Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 22,208 shares of the biopharmaceutical company's stock, valued at approximately $13,848,000.
A number of other large investors have also added to or reduced their stakes in REGN. EFG International AG bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $1,147,000. Ancora Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $39,000. Canada Pension Plan Investment Board bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $130,888,000. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $473,872,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $92,260,000. Institutional investors and hedge funds own 83.31% of the company's stock.
Insider Activity at Regeneron Pharmaceuticals
In related news, Director Huda Y. Zoghbi sold 800 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company's stock, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock worth $1,090,030 over the last three months. Company insiders own 6.97% of the company's stock.
Regeneron Pharmaceuticals Stock Performance
NASDAQ REGN opened at $833.56 on Wednesday. The firm's fifty day moving average price is $705.74 and its two-hundred day moving average price is $717.35. The stock has a market cap of $85.82 billion, a PE ratio of 20.60, a PEG ratio of 1.41 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $847.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the prior year, the company earned $12.81 EPS. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.
Regeneron Pharmaceuticals News Summary
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: An analysis titled “Regeneron: Why I Still See Upside After the Rally” reflects a continued bullish view of REGN’s long-term prospects following its recent advance. Regeneron: Why I Still See Upside After the Rally
- Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day short-interest ratio. However, the figures appear incomplete or erroneous, making them unsuitable as a meaningful trading signal.
- Negative Sentiment: Several law firms publicized a securities-fraud class action tied to Regeneron’s Phase 3 melanoma-therapy trial failure. The trial disclosure reportedly triggered a sharp selloff and erased approximately $11 billion in market value; the lawsuit alleges investors were harmed by inadequate or misleading disclosures. A September 14, 2026 deadline applies to investors seeking lead-plaintiff status. Notices were issued by Hagens Berman, Pomerantz, SueWallSt, and Portnoy Law.
- Negative Sentiment: Additional law firms, including Faruqi & Faruqi, Schall Brown & Schwartz, and Levi & Korsinsky, reiterated the pending litigation and encouraged affected shareholders to participate. The repeated announcements increase near-term legal and reputational overhang, although they do not represent new operating developments. Faruqi & Faruqi notice
Analysts Set New Price Targets
REGN has been the topic of several recent analyst reports. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Benchmark raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Truist Financial increased their price target on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating on the stock in a research note on Monday, May 18th. Finally, Canaccord Genuity Group lowered their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a research report on Tuesday, May 19th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $801.70.
Read Our Latest Research Report on REGN
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
